Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 9/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | DCTPP1 | Q9H773 | 5/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390279 | 0.90 | MEN1 (0.67) | L3MBTL1MAPK1MAPTALDH1A1DCTPP1 | |
| SCHEMBL2389087 | 0.89 | MAPT (0.68) | L3MBTL1MAPK1MAPTALDH1A1SIRT6 | |
| SCHEMBL2389705 | 0.88 | MAPT (0.65) | L3MBTL1MAPK1MAPTALDH1A1SIRT6 | |
| SCHEMBL1846574 | 0.88 | MAPT (0.69) | L3MBTL1MAPK1MAPTALDH1A1DCTPP1 | |
| SCHEMBL2389106 | 0.88 | MAPT (0.71) | L3MBTL1MAPTALDH1A1SIRT6NPSR1 | |
| SCHEMBL1848333 | 0.86 | HTR6 (0.71) | L3MBTL1MAPK1MAPTALDH1A1SIRT6 | |
| SCHEMBL1846911 | 0.84 | MAPT (0.67) | L3MBTL1MAPK1MAPTALDH1A1DCTPP1 | |
| SCHEMBL2392013 | 0.83 | MAPT (0.71) | L3MBTL1MAPK1MAPTALDH1A1DCTPP1 | |
| SCHEMBL2393159 | 0.82 | HTR6 (0.72) | MAPTALDH1A1SIRT6NPSR1HTR6 | |
| SCHEMBL2390502 | 0.82 | ALOX12 (0.71) | L3MBTL1MAPK1MAPTALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11568956-B2 | Methods for identifying inhibitors of amyloid protein aggregation | TREVENTIS CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20190050526-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2019-02-14 | — | — | US | disclosed |
| US-20160283652-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2016-09-29 | — | — | US | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | PSEN1, PSEN2, APP | L3MBTL1 2682/4885MAPK1 4130/4885MAPT 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.